Optimizing Influenza Protection in Older Adults with Diabetes: Insights from the DANFLU-2 Trial

Highlights

• High-dose inactivated influenza vaccine (HD-IIV) consistently outperforms standard-dose vaccine (SD-IIV) in reducing hospitalizations among adults aged 65 and older.
• The benefit of HD-IIV is comparable between individuals with and without diabetes for cardiorespiratory, cardiovascular, and influenza-specific hospitalizations.
• Participants with a diabetes duration of more than five years may derive a significantly greater relative benefit from high-dose vaccination regarding cardiorespiratory outcomes.
• These findings support the preferential use of HD-IIV in older populations with metabolic comorbidities to mitigate severe systemic complications of influenza.

Background